journal article·2024-02-08

The mechanisms of nanoparticle delivery to solid tumours

Luan N. M. Nguyen, Wayne Ngo, Zachary P. Lin, Shrey Sindhwani, Presley MacMillan, Stefan M. Mladjenovic, Warren C. W. Chan

Nature Reviews Bioengineering· Volume 2· Issue 3
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). This article reports that a low amount of nanoparticles (0.7% injected dose) are delivered to solid tumours.10.1038/natrevmats.2016.14 ↗
2. Papahadjopoulos, D. & Miller, N. Phospholipid model membranes. I. Structural characteristics of hydrated liquid crystals. Biochim. Biophys. Acta Biomembr. 135, 624–638 (1967).10.1016/0005-2736(67)90094-6 ↗
3. Sessa, G. & Weissmann, G. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9, 310–318 (1968).10.1016/S0022-2275(20)43097-4 ↗
4. Dong, J. et al. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells. Biomed. Pharmacother. 107, 849–859 (2018).10.1016/j.biopha.2018.08.042 ↗
5. Kim, D., Jeong, Y. Y. & Jon, S. A drug-loaded aptamer−gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4, 3689–3696 (2010).10.1021/nn901877h ↗
6. Corsi, F. et al. HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice. ACS Nano 5, 6383–6393 (2011).10.1021/nn201570n ↗
7. Cohen, H. et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther. 7, 1896–1905 (2000).10.1038/sj.gt.3301318 ↗
8. Perez, C. et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Release 75, 211–224 (2001).10.1016/S0168-3659(01)00397-2 ↗
9. Levine, R. M., Pearce, T. R., Adil, M. & Kokkoli, E. Preparation and characterization of liposome-encapsulated plasmid DNA for gene delivery. Langmuir 29, 9208–9215 (2013).10.1021/la400859e ↗
10. Mai, Y. et al. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol. 354, 104143 (2020).10.1016/j.cellimm.2020.104143 ↗
11. McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).10.1038/s41467-020-17409-9 ↗
12. Ashley, C. E. et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 6, 2174–2188 (2012).10.1021/nn204102q ↗
13. Zinger, A. et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano 13, 11008–11021 (2019).10.1021/acsnano.9b02395 ↗
14. Feczkó, T., Tóth, J., Dósa, G. & Gyenis, J. Optimization of protein encapsulation in PLGA nanoparticles. Chem. Eng. Process Process Intensif. 50, 757–765 (2011).10.1016/j.cep.2011.06.008 ↗
15. Cao, A. et al. A facile method to encapsulate proteins in silica nanoparticles: encapsulated green fluorescent protein as a robust fluorescence probe. Angew. Chem. 122, 3086–3089 (2010).10.1002/ange.200906883 ↗
16. George, T. A. et al. Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer. J. Control. Release 342, 31–43 (2022).10.1016/j.jconrel.2021.12.001 ↗
17. Ngo, W. et al. DNA-controlled encapsulation of small molecules in protein nanoparticles. J. Am. Chem. Soc. 142, 17938–17943 (2020).10.1021/jacs.0c09914 ↗
18. Yoo, H. S., Lee, K. H., Oh, J. E. & Park, T. G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates. J. Control. Release 68, 419–431 (2000).10.1016/S0168-3659(00)00280-7 ↗
19. Rayamajhi, S. et al. pH-responsive cationic liposome for endosomal escape mediated drug delivery. Colloids Surf. B Biointerfaces 188, 110804 (2020).10.1016/j.colsurfb.2020.110804 ↗
20. Palanikumar, L. et al. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun. Biol. 3, 95 (2020).10.1038/s42003-020-0817-4 ↗
21. Tai, L.-A. et al. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology 20, 135101 (2009).10.1088/0957-4484/20/13/135101 ↗
22. Sun, J., Yu, Z., Hong, C. & Pan, C. Biocompatible zwitterionic sulfobetaine copolymer‐coated mesoporous silica nanoparticles for temperature‐responsive drug release. Macromol. Rapid Commun. 33, 811–818 (2012).10.1002/marc.201100876 ↗
23. Vlasova, K. Y. et al. Magnetic liposome design for drug release systems responsive to super-low frequency alternating current magnetic field (AC MF). J. Colloid Interf. Sci. 552, 689–700 (2019).10.1016/j.jcis.2019.05.071 ↗
24. Ge, J., Neofytou, E., Cahill, T. J., Beygui, R. E. & Zare, R. N. Drug release from electric-field-responsive nanoparticles. ACS Nano 6, 227–233 (2012).10.1021/nn203430m ↗
25. Chauhan, V. P. & Jain, R. K. Strategies for advancing cancer nanomedicine. Nat. Mater. 12, 958–962 (2013).10.1038/nmat3792 ↗
26. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007). This review describes the EPR effect, that is, a passive mechanism of nanoparticle accumulation in tumours and retention due to dysfunctional tumour lymphatics.10.1038/nnano.2007.387 ↗
27. Nakamura, H., Fang, J., Jun, F. & Maeda, H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin. Drug Deliv. 12, 53–64 (2014).10.1517/17425247.2014.955011 ↗
28. Lammers, T., Kiessling, F., Hennink, W. E. & Storm, G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161, 175–187 (2012).10.1016/j.jconrel.2011.09.063 ↗
29. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986). This article established the accumulation and retention of macromolecules in solid tumours, linking these observations to tumour blood vascular leakiness and poor lymphatic drainage, providing the foundation of the EPR effect.
30. He, H., Liu, L., Morin, E. E., Liu, M. & Schwendeman, A. Survey of clinical translation of cancer nanomedicines — lessons learned from successes and failures. Acc. Chem. Res. 52, 2445–2461 (2019). This review analyses nanomedicines in clinical trials, and describes the reasons for their success and failure.10.1021/acs.accounts.9b00228 ↗
31. Nichols, J. W. & Bae, Y. H. EPR: evidence and fallacy. J. Control. Release 190, 451–464 (2014).10.1016/j.jconrel.2014.03.057 ↗
32. Danhier, F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 244, 108–121 (2016).10.1016/j.jconrel.2016.11.015 ↗
33. Nakamura, Y., Mochida, A., Choyke, P. L. & Kobayashi, H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug. Chem. 27, 2225–2238 (2016).10.1021/acs.bioconjchem.6b00437 ↗
34. Park, K. The drug delivery field at the inflection point: time to fight its way out of the egg. J. Control. Release 267, 2–14 (2017).10.1016/j.jconrel.2017.07.030 ↗
35. Sun, D., Zhou, S. & Gao, W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano 14, 12281–12290 (2020).10.1021/acsnano.9b09713 ↗
36. Weil, R. Chemotherapeutic experiments on rat tumors. J. Cancer Res. https://doi.org/10.1158/jcr.1916.95 (1916).10.1158/jcr.1916.95 ↗
37. Duran-Reynals, F. Studies on the localization of dyes and foreign proteins in normal and malignant tissues. Am. J. Cancer 3, 98–107 (1939).
38. Peterson, H.-I. & Appelgren, K. L. Experimental studies on the uptake and retention of labelled proteins in a rat tumour. Eur. J. Cancer 9, 543–547 (1973).10.1016/0014-2964(73)90142-4 ↗
39. Song, C. W. & Levitt, S. H. Quantitative study of vascularity in Walker carcinoma 256. Cancer Res. 31, 587–589 (1971).
40. Wright, R. L. Vascular permeability in experimental brain tumors. Angiology 18, 69–75 (1967).10.1177/000331976701800201 ↗
41. Gordon, R. T., Hines, J. R. & Gordon, D. Intracellular hyperthermia a biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med. Hypotheses 5, 83–102 (1979).10.1016/0306-9877(79)90063-X ↗
42. Larson, S. M. Mechanisms of localization of gallium-67 in tumors. Semin. Nucl. Med. 8, 193–203 (1978).10.1016/S0001-2998(78)80028-2 ↗
43. Som, P. et al. 97Ru-transferrin uptake in tumor and abscess. Eur. J. Nucl. Med. 8, 491–494 (1983).10.1007/BF00598908 ↗
44. O’Connor, S. W. & Bale, W. F. Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. Cancer Res. 44, 3719–3723 (1984).
45. Dvorak, H. F., Harvey, V. S. & McDonagh, J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res. 44, 3348–3354 (1984).
46. L’Abbé, M. R., Fischer, P. W. F., Trick, K. D. & Chavez, E. R. Effect of dietary selenium and tumor status on the retention of 75Se by tissues and mammary tumors of DMBA-treated rats. Biol. Trace Elem. Res. 20, 179–196 (1989).10.1007/BF02919110 ↗
47. Iwai, K., Maeda, H. & Konno, T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2115–2121 (1984).
48. Gerlowski, L. E. & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288–305 (1986).10.1016/0026-2862(86)90018-X ↗
49. Heuser, L. S. & Miller, F. N. Differential macromolecular leakage from the vasculature of tumors. Cancer 57, 461–464 (1986).10.1002/1097-0142(19860201)57:3<461::AID-CNCR2820570310>3.0.CO;2-6 ↗
50. Kreuter, J. Nanoparticle-based dmg delivery systems. J. Control. Release 16, 169–176 (1991).10.1016/0168-3659(91)90040-K ↗
51. Oppenheim, R. C. Solid colloidal drug delivery systems: nanoparticles. Int. J. Pharm. 8, 217–234 (1981).10.1016/0378-5173(81)90100-9 ↗
52. Tabata, Y., Murakami, Y. & Ikada, Y. Photodynamic effect of polyethylene glycol-modified fullerene on tumor. Jpn. J. Cancer Res. 88, 1108–1116 (1997).10.1111/j.1349-7006.1997.tb00336.x ↗
53. Allemann, E. et al. PEG‐coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT‐6 mouse mammary tumours. J. Pharm. Pharmacol. 47, 382–387 (1995).10.1111/j.2042-7158.1995.tb05815.x ↗
54. Hodoshima, N. et al. Lipid nanoparticles for delivering antitumor drugs. Int. J. Pharm. 146, 81–92 (1997).10.1016/S0378-5173(96)04779-5 ↗
55. Matsumura, Y., Oda, T. & Maeda, H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Gan Kagaku Ryoho Cancer Chemother. 14, 821–829 (1987).
56. Jain, R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559–593 (1987).10.1007/BF00047468 ↗
57. Yuan, F. et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352–3356 (1994).
58. Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995).
59. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. 95, 4607–4612 (1998). This article presents electron microscopy images of nanoparticles entering the tumour via interendothelial gaps, suggesting a mechanism of enhanced permeability of the EPR effect.10.1073/pnas.95.8.4607 ↗
60. Zhang, Y. et al. Strategies to improve tumor penetration of nanomedicines through nanoparticle design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1519 (2019).10.1002/wnan.1519 ↗
61. Bazak, R., Houri, M., Achy, S. E., Hussein, W. & Refaat, T. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol. Clin. Oncol. 2, 904–908 (2014).10.3892/mco.2014.356 ↗
62. Wang, M. & Thanou, M. Targeting nanoparticles to cancer. Pharmacol. Res. 62, 90–99 (2010).10.1016/j.phrs.2010.03.005 ↗
63. Kalyane, D. et al. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater. Sci. Eng. C 98, 1252–1276 (2019).10.1016/j.msec.2019.01.066 ↗
64. Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J. & Jain, R. K. Solid stress inhibits the growth of multicellular tumor spheroids. Nat. Biotechnol. 15, 778–783 (1997).10.1038/nbt0897-778 ↗
65. Leu, A. J., Berk, D. A., Lymboussaki, A., Alitalo, K. & Jain, R. K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324–4327 (2000).
66. Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883–1886 (2002). This article presents evidence that tumour lymphatics are dysfunctional and collapsed, suggesting a mechanism of poor lymphatic drainage of the EPR effect.10.1126/science.1071420 ↗
67. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).10.1016/S0092-8674(00)81683-9 ↗
68. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).10.1016/j.cell.2011.02.013 ↗
69. Duncan, R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm. Sci. Technol. Today 2, 441–449 (1999).10.1016/S1461-5347(99)00211-4 ↗
70. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347–360 (2003).10.1038/nrd1088 ↗
71. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161–171 (2005).10.1038/nrc1566 ↗
72. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688–701 (2006).10.1038/nrc1958 ↗
73. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457–464 (2008).10.1080/10611860701539584 ↗
74. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271–284 (2000).10.1016/S0168-3659(99)00248-5 ↗
75. Grodzinski, P., Liu, C. H., Hartshorn, C. M., Morris, S. A. & Russell, L. M. NCI alliance for nanotechnology in cancer — from academic research to clinical interventions. Biomed. Microdevices 21, 32 (2019).10.1007/s10544-019-0360-6 ↗
76. Ptak, K., Farrell, D., Panaro, N. J., Grodzinski, P. & Barker, A. D. The NCI alliance for nanotechnology in cancer: achievement and path forward. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 450–460 (2010).10.1002/wnan.98 ↗
77. Grodzinski, P. NCI cancer nanotechnology centers of excellence (CCNEs) — a full story to set the record straight. J. Control. Release 309, 341–342 (2019).10.1016/j.jconrel.2019.08.016 ↗
78. Prabhakar, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412–2417 (2013).10.1158/0008-5472.CAN-12-4561 ↗
79. Fang, J., Islam, W. & Maeda, H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug Deliv. Rev. 157, 142–160 (2020).10.1016/j.addr.2020.06.005 ↗
80. Golombek, S. K. et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv. Drug Deliv. Rev. 130, 17–38 (2018).10.1016/j.addr.2018.07.007 ↗
81. van der Meel, R. et al. Smart cancer nanomedicine.Nat. Nanotechnol. 14, 1007–1017 (2019).10.1038/s41565-019-0567-y ↗
82. Biancacci, I. et al. Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles. Adv. Sci. 9, 2103745 (2022).10.1002/advs.202103745 ↗
83. MacMillan, P. et al. Toward predicting nanoparticle distribution in heterogeneous tumor tissues. Nano Lett. 23, 7197–7205 (2023).10.1021/acs.nanolett.3c02186 ↗
84. Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A. & Lin, Z. Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach. ACS Nano 14, 3075–3095 (2020).10.1021/acsnano.9b08142 ↗
85. Dai, Q. et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 12, 8423–8435 (2018). This article established that only 0.0014% of injected nanoparticles are delivered to cancer cells.10.1021/acsnano.8b03900 ↗
86. Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumours.Nat. Mater. 22, 1261–1272 (2023). This article reports that nanoparticles exit the tumour through the lymphatics in and around the tumour, and proposes the ATR principle as an alternative mechanism of nanoparticle delivery.10.1038/s41563-023-01630-0 ↗
87. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615–627 (2010).10.1038/nrd2591 ↗
88. Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020). This article reports that active transport processes of nanoparticle entry are dominant over passive transport.10.1038/s41563-019-0566-2 ↗
89. Kingston, B. R. et al. Specific endothelial cells govern nanoparticle entry into solid tumors. ACS Nano 15, 14080–14094 (2021).10.1021/acsnano.1c04510 ↗
90. Thurston, G. et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101, 1401–1413 (1998).10.1172/JCI965 ↗
91. Feng, D., Nagy, J. A., Dvorak, H. F. & Dvorak, A. M. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor‐associated microvessels in man and animals. Microsc. Res. Tech. 57, 289–326 (2002).10.1002/jemt.10087 ↗
92. Desai, N. et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317–1324 (2006).10.1158/1078-0432.CCR-05-1634 ↗
93. Kohn, S., Nagy, J. A., Dvorak, H. F. & Dvorak, A. M. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Invest. 67, 596–607 (1992).
94. Liu, X. et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J. Clin. Investig. 127, 2007–2018 (2017).10.1172/JCI92284 ↗
95. Harney, A. S. et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932–943 (2015).10.1158/2159-8290.CD-15-0012 ↗
96. Naumenko, V. A. et al. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors. ACS Nano 13, 12599–12612 (2019).10.1021/acsnano.9b03848 ↗
97. Ballou, B. et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug. Chem. 18, 389–396 (2007).10.1021/bc060261j ↗
98. Valdés-Olmos, R. A. et al. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J. Nucl. Med. 41, 1500–1506 (2000).
99. Liang, C. et al. Tumor metastasis inhibition by imaging‐guided photothermal therapy with single‐walled carbon nanotubes. Adv. Mater. 26, 5646–5652 (2014).10.1002/adma.201401825 ↗
100. Liu, J. et al. Enhanced primary tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition. ACS Nano 13, 8648–8658 (2019).10.1021/acsnano.9b03472 ↗